Patient perspectives when switching from Cosopt® (dorzolamide-timolol) to Azarga™ (brinzolamide-timolol) for glaucoma requiring multiple drug therapy

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 2059-2062

  Auger, Graham Anthony ^a   Raynor, Mathew ^a   Longstaff, Simon ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Azarga ; Brinzolamide; Cosopt ; Dorzolamide; Side effects; Timolol

Indexed keywords

BRINZOLAMIDE PLUS TIMOLOL; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS;

ADULT; AGED; ARTICLE; BLURRED VISION; CHRONICITY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG COMBINATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE PAIN; EYE REDNESS; FEMALE; GLAUCOMA; HUMAN; MALE; QUESTIONNAIRE; STINGING; TASTE DISORDER;

EID: 84871343750     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hyperten- sion Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
2. Heijl A, Leske MC, Bengtsson B, et al. The Early Manifest Glucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
3. Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol. 1982;93:232-237.
4. Costagliola C, Omo R, Romano R, et al. Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009;10: 2859-2870.
5. Alm A. Prostaglandin derivatives as ocular hypotensive agents. Prog Retin Eye Res. 1998;17:291-312.
6. Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of rostaglandins on uveoscleral outfow. Curr Opin Ophthalmol. 2000;11:112-115.
7. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classifcation. J Glaucoma. 2003;12:393-398.
8. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863-868.
9. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once daily and adjunctive medication use. Am J Ophthalmology. 2007;144:533-540.
10. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15:132-135.
11. Kaback M, Scoper S V, Arzeno G, et al. Intraocular pressure-lowering effcacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Am Acad Ophthalmol. 2008; 115: 1728-1734.
12. Manni G, Denis P, Chew P, et al. The safety and effcacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18:293-300.
13. Mundorf TK, Rauchman SH, Williams RD, Motivol R. A patient prefer- ence comparison of Azarga™ (brinzolamide/timolol fixed combination) vs Cosopt® (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2008: 2: 623-628.
14. Doherty MD, Fraser SG, Phelan PS. Brinzolamide-timolol suspension: acceptability and side effect profile. Clin Ophthalmol. 2011;5: 419-423.
15. Rossi GCM, Pasinetti GM, Sandolo F, et al. From dorzolamide 2%/ timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study. Expert Opin Pharmacother. 2011;12:2425-2431.
16. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicentre comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol. 2000;44 Suppl 2:S141-S145.
17. Stewart WC, Day DG, Stewart JA, et al. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open angle glaucoma and ocular hypertension subjects. Eye. 2004;18:905-910.
18. Michaud JE, Friren B; International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:235-243.
19. Jampel HD, Schwartz GF, Robin AL, et al. Patient preferences for eye drop characteristics: a willingness-to-pay analysis. Arch Ophthalmol. 2003;121:540-546.